As it happened on the previous day of Q4 2018 earnings reporting, Twilio (NYSE: TWLO) stock has neared its new 52-week high price when it ended up 2.02% at $134.92 on Friday. The San Francisco-based tech firm is slated to announce its first quarter 2019 results Tuesday after market close. Twilio’s stock, which reached its 52-week high ($136.00) on March 29, 2019, contiued the positive momentum in pre-market trading hours on Monday.
Wall Street expects Twilio to swing to profit and revenue to grow 73% for the recently ended quarter. Analysts estimates Twilio to post earnings of 1 cent per share on revenue of $222.79 million. This compares with a loss of 4 cents per share on revenue of $129.1 million in the first quarter of 2018.
Active customer base is expected to continue the upward momentum, which is evidenced by the fact that it has almost quadrupled to 64,286 from the end of 2014.
Twilio had predicted first-quarter revenue to be in the range of $222 million to $225 million and non-GAAP EPS to be flat to $0.01. Base revenue was projected to be in the range of $212 million to $214 million.
For the full year 2019, the company had estimated revenue to the tune of $1.06 billion to $1.07 billion and adjusted earnings in the range of $0.08 to $0.11 per share. Base revenue is forecasted to be between $1.02 billion and $1.03 billion.
As of December 31, 2018, Twilio’s active customer accounts grew 31% year-over=year to 64,286 accounts. For the fourth quarter of 2018, the company’s earnings met expectations, while revenue beat the consensus views. The company reported an adjusted EPS of $0.04 on revenue of $204 million.
Twilio’s efforts to grow its business worldwide, its new offerings like Twilio Flex, along with its growth in enterprise customer base are expected to benefit the company.
Shares of Twilio have advanced 51% since the beginning of 2019 and jumped 218% in the past 12 months.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated